View Older Stories
-
Pernod Ricard ends merger talks with Brown-Forman
-
Bernstein SocGen Weighs on the Potential Brown Forman (BF-B) + Pernod Ricard Deal
-
Brown-Forman (BF-A) Said to Favor Sale to Pernod Ricard - Bloomberg
-
Sazerac Offered Brown-Forman $32 A Share - WSJ
-
Bernstein SocGen Weighs on Brown Forman (BF-B) Stock Amid a Potential Sazerac Deal
-
TD Cowen comments on Brown Forman (BF-B) WSJ report
-
Brown-Forman receives Sazerac approach amid Pernod talks - Bloomberg
-
Evercore comments on Brown-Forman (BF-B) WSJ Report
-
Sazerac Eyes Deal With Jack Daniel's Maker Brown-Forman - WSJ
-
RBC Capital: 'We remain cautious on Brown Forman (BF-B)'
-
Brown-Forman confirms merger discussions with Pernod Ricard
-
Citi Upgrades Brown Forman (BF-B) to Neutral
-
JPMorgan Upgrades Brown Forman (BF-B) to Neutral
-
TD Cowen: 'We view Brown-Forman as an unlikely seller'
-
Pernod Ricard Is Said To Weigh Potential Deal For Brown-Forman - Bloomberg
-
Brown Forman (BF-B) PT Lowered to $25 at UBS, Neutral Rating Maintained
-
Bernstein SocGen Group Downgrades Brown Forman (BF-B) to Market Perform
-
Brown Forman (BF-B) PT Lowered to $30 at Evercore ISI
-
Brown-Forman Sees `Two-year Headwind' On Costs, Gross Margin - Bloomberg, Citing Call
-
Brown Forman (BF-B) PT Lowered to $30 at UBS Ahead of Q3 Results
-
BNP Paribas Exane Downgrades Brown Forman (BF-B) to Underperform
-
RBC Capital Reiterates Sector Perform Rating on Brown Forman (BF-B)
-
Brown Forman (BF-B) PT Raised to $32 at Evercore ISI
-
CFRA Downgrades Brown Forman (BF-B) to Sell
-
RBC Capital Reiterates Sector Perform Rating on Brown Forman (BF-B)
-
JPMorgan Assumes Brown Forman (BF-B) at Underweight
-
TD Cowen Reiterates Hold Rating on Brown Forman (BF-B) as '1Q US Spirits Depletions Remain Weak'
-
Brown Forman (BF-B) PT Lowered to $32 at UBS as Visibility Is Limited
-
Berenberg Reiterates Hold Rating on Brown Forman (BF-B)
-
RBC Capital Reiterates Sector Perform Rating on Brown Forman (BF-B)
-
Brown Forman (BF-B) PT Raised to $33 at UBS
-
Brown Forman (BF-B) PT Raised to $33 at Barclays
-
Redburn-Atlantic Upgrades Brown Forman (BF-B) to Neutral
-
Brown Forman (BF-B) PT Lowered to $30 at UBS
-
Brown Forman (BF-B) PT Lowered at Bernstein Following 'Painful' Results
-
Bernstein on Brown Forman (BF-B): 'The Print is Painful'
-
Brown Forman (BF-B) PT Lowered to $30 at RBC Capital
-
Brown Forman (BF-B) PT Lowered to $28 at Citi
-
Brown Forman (BF-B) PT Lowered to $30 at Evercore ISI
-
Brown-Forman (BF-A) Misses Q1 EPS by 3c
-
Brown Forman (BF-B) PT Lowered to $53 at Bernstein Amid 'Trump Storm'
-
Citi Reiterates Neutral Rating on Brown Forman (BF-B)
-
Brown-Forman (BF-A) Announces Significant Evolution in U.S. Distribution
-
Berenberg Starts Brown Forman (BF-B) at Hold
-
Bernstein: 'What Is Driving US Alcohol Weakness, and Why It Matters'
-
Jack Daniels maker caught in middle of escalating EU/U.S. trade war
-
Brown Forman (BF-B) PT Raised to $39 at UBS
-
TD Cowen Reiterates Hold Rating on Brown Forman (BF-B) as 'Tariff Uncertainty Looms'
-
Brown Forman (BF-B) PT Lowered to $40 at Truist Securities
-
Brown Forman (BF-B) PT Lowered to $40 at Evercore ISI

